NCT01573052

Brief Summary

A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence, withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and alcohol craving.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Mar 2004

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2004

Completed
6.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2010

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

April 4, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 6, 2012

Completed
8.4 years until next milestone

Results Posted

Study results publicly available

August 17, 2020

Completed
Last Updated

August 17, 2020

Status Verified

August 1, 2020

Enrollment Period

6.4 years

First QC Date

April 4, 2012

Results QC Date

December 18, 2012

Last Update Submit

August 14, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Epworth Sleepiness Scale (ESS)

    ESS is an 8 item-scale and scores range between 0 and 24. The higher the score implies more daytime sleepiness.

    1 week

  • PENN Alcohol Craving Scale

    PENN is a 5 item self-rated scale of alcohol craving. Scores range from 0 (little craving for alcohol) to 30 (irresistable urge to drink alcohol)

    1 week

Secondary Outcomes (1)

  • Clinical Institute Withdrawal Assessment-Alcohol (Revised)(CIWA-Ar)

    1 week

Study Arms (2)

Chlordiazepoxide

ACTIVE COMPARATOR

Chlordiazepoxide 25mg capsule or matching placebo capsule

Drug: Chlordiazepoxide

Gabapentin

EXPERIMENTAL

Gabapentin 300mg capsule or matching placebo capsule

Drug: Gabapentin

Interventions

25mg four times daily x 3 days then tapered over 3 days

Also known as: Librium
Chlordiazepoxide

300mg four times daily x 3 days then tapered over 3 days

Also known as: Neurontin
Gabapentin

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Alcohol dependent at risk for withdrawal symptoms

You may not qualify if:

  • Benzodiazepine dependent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

George E Wahlen VA Medical Center

Salt Lake City, Utah, 84148, United States

Location

Related Publications (1)

  • Stock CJ, Carpenter L, Ying J, Greene T. Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment. Ann Pharmacother. 2013 Jul-Aug;47(7-8):961-9. doi: 10.1345/aph.1R751. Epub 2013 Jun 18.

MeSH Terms

Interventions

ChlordiazepoxideGabapentin

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsAminesOrganic Chemicalsgamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsCyclohexanecarboxylic AcidsAcids, CarbocyclicCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsAmino AcidsAmino Acids, Peptides, and Proteins

Results Point of Contact

Title
Dr. Christopher Stock
Organization
VA Salt Lake City Medical Center

Study Officials

  • Christopher J Stock, PharmD

    Salt Lake VA Health Care System

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Investigational pharmacist

Study Record Dates

First Submitted

April 4, 2012

First Posted

April 6, 2012

Study Start

March 1, 2004

Primary Completion

August 1, 2010

Study Completion

September 1, 2010

Last Updated

August 17, 2020

Results First Posted

August 17, 2020

Record last verified: 2020-08

Locations